Universitätsklinikum Essen (AöR), Klinik f. Hämatologie u. Stammzelltransplantation
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hanoun, Maher
VINCENT, NCT05904106 / 2021-003248-26: Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

Recruiting
2
146
Europe
Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin
Technische Universität Dresden, University Hospital Heidelberg, AbbVie
Acute Myeloid Leukemia
09/28
09/28
RELAX, NCT04330820 / 2018-003025-28: Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax

Active, not recruiting
1/2
55
Europe
Venetoclax Oral Tablet, Cytarabin
Technische Universität Dresden, AbbVie
Relapsed Adult AML, Refractory AML
10/23
08/25
MOSAIC, NCT04385290 / 2019-003863-23: Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia

Recruiting
1/2
214
Europe
MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin
Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer
Acute Myeloid Leukemia
04/27
04/28

Download Options